Non small cell lung cancer
Conditions
Interventions
Preoperative Chemotherapy (1) Docetaxel (DOC) 250ml infusion of glucose injection, saline solution, mixed with an electrolyte maintenance solution, intravenous infusion over 60 min. (2) Carboplatin
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: lung cancer 2) Patients showed pathological mediastinal lymph node metastases , FDG-PET and chest CT scans showed significant enlargement of mediastinal lymph nodes on patients with N2. Or, in the thoracic organ tumors (heart, major blood vessel, trachea, and vertebrate ) patients with T4 invasion admit. 3) No history of radiotherapy and chemotherapy in initial treatment for lung cancer 4) Over 20 years of age, less than 75 years old 5) ECOG Performance status :0-1 6) Patients with adequate organ function WBC 4000/mm3 or more, 12000/mm3 less Hb 10.0g/dl Plt 100000/mm3 more GOT, GPT 2 times the upper limit of normal for the facility T. Bil 1.5mg/dl or less sCr 1.5mg/dl or less PaO2 70Torr more Than expected after FEV1.0 0.8L 7) Measurable disease (at least 1 target lesion 2cm or more) Patients 8) Written Informed concent was obtained in those patients
Exclusion criteria
Exclusion criteria: ) Blood transfusion within 14 days of therapy before enrollment, and preparations are treated with hematopoietic factor, those patients treated with antithrombotic agents for thrombosis. 2) Severe renal dysfunction, or urine protein 2+ or more cases. 3) Patient with severe drug allergy (anaphylaxis) 4) Patients with active double cancer 5) Patients with infectious diseases as a clinical problem, and suspected. 6) Poorly controlled hypertension, or patients with diabetes. 7) Significant ECG abnormalities, patients with heart disease as a clinical problem. 8) Patients with a history mager of Thrombosis or thrombosis severe lung disease within one year of the merger or previous thrombosis, severe lung disease (interstitial pneumonitis, pulmonary fibrosis, severe emphysema, etc.) within one year. 9) Patients with non-healing traumatic fracture 10) Patients with a history of mental disability, central nervus system disorder, cerebrovascular disease 11) In addition, patients who are considered not to participate in the study by doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate (ORR) Overall survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Histological effects Complete resection Progression free survival (PFS) Safety 2-year survival rate | — |
Countries
Japan
Contacts
Public ContactKazutoshi Isobe
Toho University Omori Medical Center Division of Respiratory Medicine
Outcome results
None listed